Company Profile
Naviscan
Molecular Diagnostics
Imaging
11180 Roselle Street
Suite 100
San Diego, CA 92121
USA
www.naviscanpet.com
|
Incorporated in 1995
37 Employees
|
Privately Held
|
|
This Year's Highlights
- Naviscan is currently conducting a prospective, multicenter clinical trial at five study sites comparing images with PEM (positron emission mammography) to MR (magnetic resonance) in pre-surgical planning of breast cancer patients.
- Naviscan recruited Paul J. Mirabella as the company's new President and CEO in July 2007. Paul brings more than 30 years experience in diagnostic imaging with GE and will instrumental in the company's growth in the field of molecular imaging.
- Naviscan completed a $15 million Series C round of financing in May 2007 with lead investor, QuestMark Partners. Sanderling Ventures, Mayo Medical Ventures and Walker Ventures, previous Series B investors joined the round as well.
|
Anticipated Highlights
- Naviscan will launch a new addition to the PEM Flex Solo II scanner in Q1 2008.
- Naviscan will complete the multicenter clinical trial comparing PEM and MR in pre-surgical planning of breast cancer patients at five study sites in the second half of 2008. A preliminary analysis of the data is expected in the second quarter.
- Naviscan will commence clinical trials of its new B12 radiotracer in Q1, 2008.
|
|
Corporate Mission
Naviscan PET Systems develops and markets compact, organ specific, high-resolution PET scanners and molecular agents used for high-resolution molecular imaging. These products are designed to help physicians and researchers diagnose and locate cancer, guide interventions, and advance new clinical therapies.
|
